Roche moves obesity drug to pivotal trials after mid-stage success
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Analysis-Alzheimer’s drug hunt learns from cancer fight’s multi-target playbook
By Deena Beasley Dec 12 (Reuters) – Alzheimer’s trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their…
FDA reviewers didn’t get to vote on first priority voucher drug
WASHINGTON — The Food and Drug Administration has promised companies that earn a Commissioner’s National Priority Voucher a one-…
AbbVie parts ways with Calico
Unexpected uncoupling raises questions about the pace – and patience – of longevity drug discovery amid shifting pharma…
Countries used to test drugs often don’t see the approved medicines, study finds
Numerous medicines are not accessible in many of the countries where they were tested before approval by the…
3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs
Eli Lilly has been investing in radiopharmaceuticals, which can help revolutionize cancer care in the future. Its early…
New FDA priority review vouchers go to Lilly, Novo, Vertex
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s…
Eli Lilly, Sarepta, Pfizer, Medicare, Novo: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Synthetic lethality in cancer drug discovery: challenges and opportunities
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches…
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…
Breakthrough blood pressure drug could be on NHS next year
A new daily pill for high blood pressure is set to revolutionise treatment for the first time in…
IL6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic risk
GBD Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204…